This exciting news in the cell therapy sector could revolutionize how quickly life-changing therapies reach patients.
BioCentriq, a leading cell therapy contract development and manufacturing organization (CDMO), is set to expand its operations and establish a cutting-edge cell therapy manufacturing facility in Princeton, New Jersey.
This facility will become BioCentriq’s new headquarters, marking a significant step forward for the company.
BioCentriq is investing $12 million in facility upgrades, equipment, and business system enhancements at the Princeton location.
The 60,000-square-foot site boasts six independent ISO 7 cleanrooms equipped with advanced manufacturing technologies.
This expansion includes a regional manufacturing network with BioCentriq’s already established location in Newark, NJ.
The Newark facility will continue to operate as a clinical GMP production center and a hub for specialized training and workforce development.
BioCentriq’s strategic capital investments and expanded infrastructure allow them to offer a full range of services, including technology transfer, process and analytical development, GMP manufacturing, quality control lot release, and stability testing services.
Listen to full details in our latest podcast episode below: